{"nctId":"NCT02118961","briefTitle":"Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents","startDateStruct":{"date":"2014-04"},"conditions":["Diphtheria","Tetanus","Pertussis"],"count":446,"armGroups":[{"label":"BK1301","type":"EXPERIMENTAL","interventionNames":["Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)"]},{"label":"DT toxoid","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)"]}],"interventions":[{"name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)","otherNames":["TRIBIK®"]},{"name":"Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)","otherNames":["DTBIK®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 11 or 12 years on the day of injection\n* Received 3 or 4 doses of DTaP vaccine\n\nExclusion Criteria:\n\n* History of pertussis, diphtheria, tetanus\n* History of anaphylaxis to vaccine components\n* Serious conditions or diseases of the heart, vein, blood, respiratory, hepar, kidney, digestive system, psychiatric or nervous system\n* Transfused or received gamma globulin within 3 months, or received high-dose gamma globulin within 6 months before the day of injection","healthyVolunteers":true,"sex":"ALL","minimumAge":"11 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies","description":"Booster response was defined as post titer ≥ 0.4 IU/mL and post/pre titer ≥ 4 increase.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Booster Responses for Anti-pertussis Toxoid (Anti-PT) and Anti-Filamentous Hemagglutinin (Anti-FHA) Antibodies","description":"Booster response was defined as post titer ≥ 20 EU/mL and post/pre titer ≥ 4 increase in a subject with pre titer \\< 20 EU/mL, or post/pre titer ≥ 2 increase in a subject with pre titer ≥ 20 EU/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-D and Anti-T Antibody Titers Above Protocol Defined Cut-off Values","description":"Protocol defined cut-off values were 0.1 IU/mL for anti-D and 0.01 IU/mL for anti-T.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-PT and Anti-FHA Antibody Titers Above Protocol Defined Cut-off Values","description":"Protocol defined cut-off values were 10 EU/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Anti-D and Anti-T Antibodies","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.856","spread":null},{"groupId":"OG001","value":"15.581","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.378","spread":null},{"groupId":"OG001","value":"11.638","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Anti-PT and Anti-FHA Antibodies","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344.46","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer Ratios of Anti-D and Anti-T Antibodies","description":"Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137.5","spread":null},{"groupId":"OG001","value":"106.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":null},{"groupId":"OG001","value":"44.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer Ratios of Anti-PT and Anti-FHA Antibodies","description":"Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":223},"commonTop":["Injection site erythema","Injection site swelling","Injection site pruritus","Injection site pain","Injection site warmth"]}}}